Navigation Links
Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
Date:12/21/2009

SAN MARINO, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Biotechnology company Viral Genetics (Pink Sheets: VRAL) today announced that it filed an updated Information Statement including unaudited consolidated financial statements for the nine months ended September 30, 2009, as well as year-end statements for December 31, 2008 and 2007. This document is available in PDF form free of charge via the www.pinksheets.com website after entering the Company's ticker symbol and clicking "Filings". The Information Statement is a comprehensive disclosure document that describes the Company, its business, its products, risk factors, and financial performance.

About Viral Genetics Inc.

Headquartered in San Marino, Calif., Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an exclusive license agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc., to advance a technology developed by University of Colorado Professor M. Karen Newell called "metabolic disruption technology" (MDT), which focuses on blocking a tumor cell's ability to generate energy from glucose or from fatty acids. Viral Genetics recently acquired exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado. Online at www.viralgenetics.com.

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of VGV-1 in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Contact: Viral Genetics, Haig Keledjian, 626-334-5310

SOURCE Viral Genetics


'/>"/>
SOURCE Viral Genetics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
10. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
11. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... PUNE, India , May 30, 2016 ... new market research report "Healthcare Biometrics Market ... Behavioral (Signature, Voice)), Multifactor, Multimodal), Application (Workforce ... Global Forecast to 2021", published by MarketsandMarkets, ... 2,848.3 Million by 2021 from USD 1,182.6 ...
(Date:5/30/2016)... May 30, 2016 - DCGI grants limited ... to Buerger,s disease - Stempeucel® becomes 5th off-the-shelf Stem ... the world - Buerger,s Disease (also known as Thromboangiitis ... and Globally - Prevalence of Buerger,s Disease ... and 2 per 10,000 persons in the European Community & ...
(Date:5/27/2016)... 2016 LabStyle Innovations Corp . ... Tool, today announced that the Company,s Chief Financial Officer, ... being held June 1-2 in New York, NY ... 7-9 in Los Angeles, CA. ... and operational milestones, including the U.S. FDA Clearance and commercial ...
Breaking Medicine Technology:
(Date:5/31/2016)... , ... May 31, 2016 ... ... healthcare that considers individuals’ genetic characteristics and the physical and behavioral worlds ... work in sync. In personalized medicine, diagnosing an individual’s disease depends on ...
(Date:5/31/2016)... HOUSTON, TEXAS (PRWEB) , ... May 31, 2016 ... ... is live in Greater Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables ... prior medical records for their patients from other participating organizations in the exchange. ...
(Date:5/31/2016)... ... 31, 2016 , ... CallTrackingMetrics's software gives healthcare ... the performance of sales and support staff, and to efficiently route calls to ... customers to record, transcribe, route, document, and report on everything going on in ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
Breaking Medicine News(10 mins):